Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.22 USD
+0.52 (1.14%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $46.23 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 46.22 +0.52(1.14%)
Will AGIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Other News for AGIO
Small-cap and mid-cap Health Care has room to rally - Roth MKM
Piper Sandler Sticks to Its Buy Rating for Agios Pharma (AGIO)
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Closing Bell Movers: Airbnb, TripAdvisor down double digits on earnings
Agios to receive $1.1B in milestone payments for vorasidenib approval